This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2015 Sep 3;373(10):981.

doi: 10.1056/NEJMc1508385.

Vasopressin Antagonists

PMID: 26332561
DOI: 10.1056/NEJMc1508385

Comment

Vasopressin Antagonists

Tomas Berl. N Engl J Med. 2015.

. 2015 Sep 3;373(10):981.

doi: 10.1056/NEJMc1508385.

Author

PMID: 26332561
DOI: 10.1056/NEJMc1508385

No abstract available

PubMed Disclaimer

Comment on

Vasopressin antagonists.
Berl T. Berl T. N Engl J Med. 2015 Jun 4;372(23):2207-16. doi: 10.1056/NEJMra1403672. N Engl J Med. 2015. PMID: 26039601 Review. No abstract available.
Vasopressin Antagonists.
Vandergheynst F, Gankam Kengne F, Decaux G. Vandergheynst F, et al. N Engl J Med. 2015 Sep 3;373(10):980-1. doi: 10.1056/NEJMc1508385. N Engl J Med. 2015. PMID: 26332562 No abstract available.

Similar articles

Vasopressin Antagonists.
Vandergheynst F, Gankam Kengne F, Decaux G. Vandergheynst F, et al. N Engl J Med. 2015 Sep 3;373(10):980-1. doi: 10.1056/NEJMc1508385. N Engl J Med. 2015. PMID: 26332562 No abstract available.
Vasopressin antagonists.
Berl T. Berl T. N Engl J Med. 2015 Jun 4;372(23):2207-16. doi: 10.1056/NEJMra1403672. N Engl J Med. 2015. PMID: 26039601 Review. No abstract available.
Vasopressin receptor antagonists: Characteristics and clinical role.
Rondon-Berrios H, Berl T. Rondon-Berrios H, et al. Best Pract Res Clin Endocrinol Metab. 2016 Mar;30(2):289-303. doi: 10.1016/j.beem.2016.02.004. Epub 2016 Feb 16. Best Pract Res Clin Endocrinol Metab. 2016. PMID: 27156765 Review.
[The pathway of vasopressin as a pharmacological target in nephrology: a narrative review].
Recupero M, Fulignati P, Naticchia A, D'Alonzo S, D'Ascenzo F, Costanzi S. Recupero M, et al. G Ital Nefrol. 2018 Dec;35(6):2018-vol6. G Ital Nefrol. 2018. PMID: 30550035 Review. Italian.
Vasopressin receptor antagonists in patients with chronic heart failure.
De Vecchis R, Cantatrione C, Mazzei D. De Vecchis R, et al. Herz. 2017 Aug;42(5):492-497. doi: 10.1007/s00059-016-4482-9. Epub 2016 Sep 15. Herz. 2017. PMID: 27628642 Review. English.

See all similar articles

Cited by

Benefit of tolvaptan in the management of hyponatraemia in patients with diuretic-refractory congestive heart failure: the SEMI-SEC project.
Pose A, Almenar L, Gavira JJ, López-Granados A, Blasco T, Delgado J, Aramburu O, Rodríguez A, Manzano L, Manito N. Pose A, et al. ESC Heart Fail. 2017 May;4(2):130-137. doi: 10.1002/ehf2.12124. Epub 2017 Jan 19. ESC Heart Fail. 2017. PMID: 28451449 Free PMC article.
Novel Potential Therapeutic Targets in Autosomal Dominant Polycystic Kidney Disease from the Perspective of Cell Polarity and Fibrosis.
Ahn Y, Park JH. Ahn Y, et al. Biomol Ther (Seoul). 2024 May 1;32(3):291-300. doi: 10.4062/biomolther.2023.207. Epub 2024 Apr 9. Biomol Ther (Seoul). 2024. PMID: 38589290 Free PMC article. Review.
Acute and Chronic Hyponatremia.
Kheetan M, Ogu I, Shapiro JI, Khitan ZJ. Kheetan M, et al. Front Med (Lausanne). 2021 Aug 3;8:693738. doi: 10.3389/fmed.2021.693738. eCollection 2021. Front Med (Lausanne). 2021. PMID: 34414205 Free PMC article. Review.
Vasopressin antagonist efficacy and safety in volume-overloaded critically ill patients: a new therapeutic alternative.
Ruiz-Ramos J, Ramírez P, Broch MJ, Gordon M, Villarreal E, Pinos A, Sosa M, Castellanos-Ortega Á. Ruiz-Ramos J, et al. Eur J Hosp Pharm. 2020 May;27(3):157-161. doi: 10.1136/ejhpharm-2018-001664. Epub 2018 Nov 10. Eur J Hosp Pharm. 2020. PMID: 32419936 Free PMC article.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.